Daniel Perkins is the Co-Director of the Melbourne-based non-profit organisation Psychae Institute, which conducts research on botanical psychedelics with the aim of progressing these as registered medical treatments. He is also an Adjunct Associate Professor at the Centre for Mental Health, Swinburne University, and a Senior Research Fellow at the School of Population and Global Health at the University of Melbourne. After spending time in Peru in 2012 and witnessing remarkable ayahuasca induced reported improvements in mental and physical health conditions, Daniel led the commencement of Australia’s first ayahuasca and mental health studies at the University of Melbourne, which grew to involve an international team of researchers from Brazil, Spain, Switzerland, and the Czech Republic collecting data from more than 10,000 ayahuasca drinkers in over 50 countries. He has led a range of other research relating to ayahuasca and medicinal cannabis, is a chief investigator on an NHMRC Phase 2 DMT-harmala alkaloid RCT study, and is co-founder of the University of Melbourne's Medicinal Psychedelics Research Network. Daniel also has a strong policy and regulation interest and was previously Director of the Victorian government’s Office of Medicinal Cannabis.

Website: www.psychae.org